nodes	percent_of_prediction	percent_of_DWPC	metapath
Rasagiline—BCL2—prostate gland—urinary bladder cancer	0.0174	0.145	CbGeAlD
Rasagiline—CYP1A2—urine—urinary bladder cancer	0.0144	0.119	CbGeAlD
Rasagiline—BCL2—epithelium—urinary bladder cancer	0.0128	0.106	CbGeAlD
Rasagiline—BCL2—smooth muscle tissue—urinary bladder cancer	0.0123	0.102	CbGeAlD
Rasagiline—BCL2—renal system—urinary bladder cancer	0.0119	0.0986	CbGeAlD
Rasagiline—BCL2—female reproductive system—urinary bladder cancer	0.00949	0.079	CbGeAlD
Rasagiline—MAOB—prostate gland—urinary bladder cancer	0.00724	0.0602	CbGeAlD
Rasagiline—MAOB—seminal vesicle—urinary bladder cancer	0.00613	0.0509	CbGeAlD
Rasagiline—BCL2—lymph node—urinary bladder cancer	0.00555	0.0462	CbGeAlD
Rasagiline—MAOB—renal system—urinary bladder cancer	0.00494	0.041	CbGeAlD
Rasagiline—MAOB—urethra—urinary bladder cancer	0.00485	0.0403	CbGeAlD
Rasagiline—MAOB—female reproductive system—urinary bladder cancer	0.00395	0.0329	CbGeAlD
Rasagiline—MAOB—vagina—urinary bladder cancer	0.00358	0.0297	CbGeAlD
Rasagiline—CYP1A2—renal system—urinary bladder cancer	0.00351	0.0292	CbGeAlD
Rasagiline—MAOB—lymph node—urinary bladder cancer	0.00231	0.0192	CbGeAlD
Rasagiline—BCL2—Ceramide signaling pathway—MYC—urinary bladder cancer	0.000914	0.00263	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—GPX1—urinary bladder cancer	0.00091	0.00262	CbGpPWpGaD
Rasagiline—BCL2—Intrinsic Pathway for Apoptosis—TP53—urinary bladder cancer	0.000905	0.00261	CbGpPWpGaD
Rasagiline—BCL2—Amyotrophic lateral sclerosis (ALS)—TP53—urinary bladder cancer	0.000905	0.00261	CbGpPWpGaD
Rasagiline—MAOB—Biological oxidations—GSTP1—urinary bladder cancer	0.000903	0.0026	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.000893	0.00257	CbGpPWpGaD
Rasagiline—BCL2—ATF-2 transcription factor network—EP300—urinary bladder cancer	0.000889	0.00256	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—EP300—urinary bladder cancer	0.000889	0.00256	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—CDKN1A—urinary bladder cancer	0.000887	0.00255	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—SRC—urinary bladder cancer	0.000865	0.00249	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CDKN2A—urinary bladder cancer	0.000862	0.00248	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CDKN2A—urinary bladder cancer	0.000862	0.00248	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PRSS3—urinary bladder cancer	0.000857	0.00247	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—FAS—urinary bladder cancer	0.000852	0.00245	CbGpPWpGaD
Rasagiline—BCL2—Ceramide signaling pathway—TNF—urinary bladder cancer	0.000852	0.00245	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—EP300—urinary bladder cancer	0.000844	0.00243	CbGpPWpGaD
Rasagiline—CYP1A2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000835	0.0024	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—MYC—urinary bladder cancer	0.000832	0.0024	CbGpPWpGaD
Rasagiline—MAOB—Biological oxidations—GSTM1—urinary bladder cancer	0.00083	0.00239	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—RHOA—urinary bladder cancer	0.000828	0.00238	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—RB1—urinary bladder cancer	0.00082	0.00236	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—IGF1—urinary bladder cancer	0.000813	0.00234	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—CDKN2A—urinary bladder cancer	0.000809	0.00233	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—PTGS2—urinary bladder cancer	0.000806	0.00232	CbGpPWpGaD
Rasagiline—BCL2—Integrated Cancer Pathway—TP53—urinary bladder cancer	0.000805	0.00232	CbGpPWpGaD
Rasagiline—BCL2—IL-2 Signaling Pathway—HRAS—urinary bladder cancer	0.000799	0.0023	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—FAS—urinary bladder cancer	0.000785	0.00226	CbGpPWpGaD
Rasagiline—BCL2—Interleukin-11 Signaling Pathway—HRAS—urinary bladder cancer	0.00077	0.00222	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—KRAS—urinary bladder cancer	0.000769	0.00221	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000763	0.0022	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.00075	0.00216	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.000748	0.00216	CbGpPWpGaD
Rasagiline—BCL2—Caspase Cascade in Apoptosis—TNF—urinary bladder cancer	0.000742	0.00214	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000738	0.00213	CbGpPWpGaD
Rasagiline—BCL2—Validated targets of C-MYC transcriptional repression—MYC—urinary bladder cancer	0.000735	0.00212	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CCND1—urinary bladder cancer	0.000728	0.0021	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—CXCL8—urinary bladder cancer	0.000727	0.00209	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—RHOA—urinary bladder cancer	0.000723	0.00208	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CDKN2A—urinary bladder cancer	0.000721	0.00208	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000719	0.00207	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.000719	0.00207	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000709	0.00204	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000709	0.00204	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—ATM—urinary bladder cancer	0.000709	0.00204	CbGpPWpGaD
Rasagiline—BCL2—IL-3 Signaling Pathway—HRAS—urinary bladder cancer	0.000706	0.00203	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CDK4—urinary bladder cancer	0.000706	0.00203	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—CDKN1A—urinary bladder cancer	0.000705	0.00203	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—ESR1—urinary bladder cancer	0.000703	0.00202	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN2A—urinary bladder cancer	0.0007	0.00202	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.0007	0.00202	CbGpPWpGaD
Rasagiline—BCL2—Corticotropin-releasing hormone—IL2—urinary bladder cancer	0.000695	0.002	CbGpPWpGaD
Rasagiline—BCL2—Signaling events mediated by Stem cell factor receptor (c-Kit)—HRAS—urinary bladder cancer	0.000684	0.00197	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—EP300—urinary bladder cancer	0.00067	0.00193	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—ERBB2—urinary bladder cancer	0.000669	0.00193	CbGpPWpGaD
Rasagiline—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.000664	0.00191	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.000664	0.00191	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—CREBBP—urinary bladder cancer	0.000654	0.00188	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CXCL8—urinary bladder cancer	0.000654	0.00188	CbGpPWpGaD
Rasagiline—BCL2—IL2-mediated signaling events—HRAS—urinary bladder cancer	0.000653	0.00188	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—RB1—urinary bladder cancer	0.000652	0.00188	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.000649	0.00187	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00064	0.00184	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—RB1—urinary bladder cancer	0.000613	0.00177	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CDH1—urinary bladder cancer	0.000611	0.00176	CbGpPWpGaD
Rasagiline—BCL2—Kit receptor signaling pathway—HRAS—urinary bladder cancer	0.000609	0.00175	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—CDH1—urinary bladder cancer	0.000599	0.00172	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CCND1—urinary bladder cancer	0.000591	0.0017	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—CDKN1A—urinary bladder cancer	0.000589	0.0017	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—PTEN—urinary bladder cancer	0.000588	0.00169	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	0.000587	0.00169	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	0.000585	0.00168	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.000584	0.00168	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—MYC—urinary bladder cancer	0.000584	0.00168	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—MYC—urinary bladder cancer	0.000584	0.00168	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	0.000582	0.00168	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000576	0.00166	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—CDKN1A—urinary bladder cancer	0.000572	0.00165	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—BIRC3—urinary bladder cancer	0.000572	0.00165	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—PTEN—urinary bladder cancer	0.000571	0.00164	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTZ1—urinary bladder cancer	0.000553	0.00159	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—SRC—urinary bladder cancer	0.000545	0.00157	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNF—urinary bladder cancer	0.000544	0.00157	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—KRAS—urinary bladder cancer	0.00054	0.00155	CbGpPWpGaD
Rasagiline—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	0.000531	0.00153	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NAT1—urinary bladder cancer	0.000524	0.00151	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—GSTO2—urinary bladder cancer	0.000524	0.00151	CbGpPWpGaD
Rasagiline—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	0.000515	0.00148	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	0.00051	0.00147	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—IGF1—urinary bladder cancer	0.000506	0.00146	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	0.000504	0.00145	CbGpPWpGaD
Rasagiline—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000503	0.00145	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PRSS3—urinary bladder cancer	0.000499	0.00144	CbGpPWpGaD
Rasagiline—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000494	0.00142	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TP53—urinary bladder cancer	0.00048	0.00138	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—UGT2B7—urinary bladder cancer	0.000479	0.00138	CbGpPWpGaD
Rasagiline—BCL2—Immune System—VHL—urinary bladder cancer	0.000476	0.00137	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—MYC—urinary bladder cancer	0.000474	0.00137	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—CDKN1A—urinary bladder cancer	0.000468	0.00135	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—PTEN—urinary bladder cancer	0.000467	0.00135	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—RHOA—urinary bladder cancer	0.000464	0.00133	CbGpPWpGaD
Rasagiline—BCL2—C-MYB transcription factor network—HRAS—urinary bladder cancer	0.000459	0.00132	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	0.000456	0.00131	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis Modulation and Signaling—TP53—urinary bladder cancer	0.00045	0.0013	CbGpPWpGaD
Rasagiline—BCL2—Immune System—MT2A—urinary bladder cancer	0.000448	0.00129	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—EP300—urinary bladder cancer	0.000446	0.00128	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	0.00044	0.00127	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—KRAS—urinary bladder cancer	0.000438	0.00126	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.000433	0.00125	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CYP4B1—urinary bladder cancer	0.000432	0.00124	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—ERBB2—urinary bladder cancer	0.000429	0.00124	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	0.000427	0.00123	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	0.000419	0.00121	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	0.000418	0.0012	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—SLC19A1—urinary bladder cancer	0.000408	0.00117	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—TP53—urinary bladder cancer	0.000401	0.00116	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PRSS3—urinary bladder cancer	0.000397	0.00114	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—TP53—urinary bladder cancer	0.00039	0.00112	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.000389	0.00112	CbGpPWpGaD
Rasagiline—BCL2—Senescence and Autophagy in Cancer—HRAS—urinary bladder cancer	0.000384	0.00111	CbGpPWpGaD
Rasagiline—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000383	0.0011	CbGpPWpGaD
Rasagiline—BCL2—Direct p53 effectors—EGFR—urinary bladder cancer	0.00038	0.00109	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—CCND1—urinary bladder cancer	0.000379	0.00109	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000378	0.00109	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	0.000378	0.00109	CbGpPWpGaD
Rasagiline—BCL2—DNA Damage Response (only ATM dependent)—HRAS—urinary bladder cancer	0.000373	0.00107	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—PTEN—urinary bladder cancer	0.000366	0.00105	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	0.000365	0.00105	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	0.000365	0.00105	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	0.000364	0.00105	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—IFNA2—urinary bladder cancer	0.00036	0.00104	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	0.000357	0.00103	CbGpPWpGaD
Rasagiline—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.000357	0.00103	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	0.000348	0.001	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—S100B—urinary bladder cancer	0.00034	0.00098	CbGpPWpGaD
Rasagiline—BCL2—Focal Adhesion—SRC—urinary bladder cancer	0.000339	0.000977	CbGpPWpGaD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	0.000338	0.000973	CbGpPWpGaD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	0.000338	0.000972	CbGpPWpGaD
Rasagiline—BCL2—Apoptosis—TNF—urinary bladder cancer	0.000333	0.00096	CbGpPWpGaD
Rasagiline—BCL2—Immune System—BIRC3—urinary bladder cancer	0.000333	0.000959	CbGpPWpGaD
Rasagiline—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000328	0.000945	CbGpPWpGaD
Rasagiline—Haemoglobin—Methotrexate—urinary bladder cancer	0.000321	0.000603	CcSEcCtD
Rasagiline—Haemorrhage—Methotrexate—urinary bladder cancer	0.000319	0.0006	CcSEcCtD
Rasagiline—Sweating—Epirubicin—urinary bladder cancer	0.000319	0.0006	CcSEcCtD
Rasagiline—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000319	0.0006	CcSEcCtD
Rasagiline—BCL2—Direct p53 effectors—TP53—urinary bladder cancer	0.000319	0.000918	CbGpPWpGaD
Rasagiline—Asthenia—Gemcitabine—urinary bladder cancer	0.000318	0.000598	CcSEcCtD
Rasagiline—MAOB—Metabolism—TYMP—urinary bladder cancer	0.000318	0.000915	CbGpPWpGaD
Rasagiline—Haematuria—Epirubicin—urinary bladder cancer	0.000318	0.000596	CcSEcCtD
Rasagiline—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000315	0.000592	CcSEcCtD
Rasagiline—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000315	0.000592	CcSEcCtD
Rasagiline—Epistaxis—Epirubicin—urinary bladder cancer	0.000314	0.00059	CcSEcCtD
Rasagiline—Pruritus—Gemcitabine—urinary bladder cancer	0.000314	0.00059	CcSEcCtD
Rasagiline—Nausea—Thiotepa—urinary bladder cancer	0.000313	0.000588	CcSEcCtD
Rasagiline—Urethral disorder—Methotrexate—urinary bladder cancer	0.000313	0.000588	CcSEcCtD
Rasagiline—Weight decreased—Doxorubicin—urinary bladder cancer	0.000313	0.000587	CcSEcCtD
Rasagiline—Feeling abnormal—Etoposide—urinary bladder cancer	0.000312	0.000586	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000311	0.000895	CbGpPWpGaD
Rasagiline—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000311	0.000895	CbGpPWpGaD
Rasagiline—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00031	0.000582	CcSEcCtD
Rasagiline—Pruritus—Fluorouracil—urinary bladder cancer	0.000309	0.00058	CcSEcCtD
Rasagiline—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000308	0.000579	CcSEcCtD
Rasagiline—Infestation—Doxorubicin—urinary bladder cancer	0.000308	0.000579	CcSEcCtD
Rasagiline—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000305	0.000572	CcSEcCtD
Rasagiline—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000304	0.00057	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	0.000303	0.000872	CbGpPWpGaD
Rasagiline—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000302	0.000567	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000301	0.000868	CbGpPWpGaD
Rasagiline—Urticaria—Etoposide—urinary bladder cancer	0.000301	0.000565	CcSEcCtD
Rasagiline—Haemoglobin—Epirubicin—urinary bladder cancer	0.0003	0.000564	CcSEcCtD
Rasagiline—Jaundice—Doxorubicin—urinary bladder cancer	0.0003	0.000564	CcSEcCtD
Rasagiline—Stomatitis—Doxorubicin—urinary bladder cancer	0.0003	0.000564	CcSEcCtD
Rasagiline—BCL2—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	0.0003	0.000864	CbGpPWpGaD
Rasagiline—Rhinitis—Epirubicin—urinary bladder cancer	0.0003	0.000563	CcSEcCtD
Rasagiline—Abdominal pain—Etoposide—urinary bladder cancer	0.0003	0.000562	CcSEcCtD
Rasagiline—Body temperature increased—Etoposide—urinary bladder cancer	0.0003	0.000562	CcSEcCtD
Rasagiline—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.0003	0.000562	CcSEcCtD
Rasagiline—Haemorrhage—Epirubicin—urinary bladder cancer	0.000299	0.000561	CcSEcCtD
Rasagiline—Eye disorder—Methotrexate—urinary bladder cancer	0.000299	0.000561	CcSEcCtD
Rasagiline—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000299	0.000561	CcSEcCtD
Rasagiline—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000297	0.000559	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—EGFR—urinary bladder cancer	0.000297	0.000857	CbGpPWpGaD
Rasagiline—Asthenia—Cisplatin—urinary bladder cancer	0.000297	0.000557	CcSEcCtD
Rasagiline—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000296	0.000557	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	0.000296	0.000853	CbGpPWpGaD
Rasagiline—Sweating—Doxorubicin—urinary bladder cancer	0.000295	0.000555	CcSEcCtD
Rasagiline—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000295	0.000554	CcSEcCtD
Rasagiline—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000295	0.000553	CcSEcCtD
Rasagiline—BCL2—Apoptosis—TP53—urinary bladder cancer	0.000294	0.000846	CbGpPWpGaD
Rasagiline—Haematuria—Doxorubicin—urinary bladder cancer	0.000294	0.000552	CcSEcCtD
Rasagiline—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000294	0.000552	CcSEcCtD
Rasagiline—Urethral disorder—Epirubicin—urinary bladder cancer	0.000293	0.00055	CcSEcCtD
Rasagiline—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000291	0.000838	CbGpPWpGaD
Rasagiline—Epistaxis—Doxorubicin—urinary bladder cancer	0.000291	0.000546	CcSEcCtD
Rasagiline—Angiopathy—Methotrexate—urinary bladder cancer	0.00029	0.000544	CcSEcCtD
Rasagiline—Immune system disorder—Methotrexate—urinary bladder cancer	0.000289	0.000542	CcSEcCtD
Rasagiline—Dizziness—Fluorouracil—urinary bladder cancer	0.000289	0.000542	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000288	0.00083	CbGpPWpGaD
Rasagiline—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000288	0.000541	CcSEcCtD
Rasagiline—MAOB—Metabolism—NAT2—urinary bladder cancer	0.000287	0.000827	CbGpPWpGaD
Rasagiline—Chills—Methotrexate—urinary bladder cancer	0.000287	0.000538	CcSEcCtD
Rasagiline—Diarrhoea—Cisplatin—urinary bladder cancer	0.000283	0.000531	CcSEcCtD
Rasagiline—Alopecia—Methotrexate—urinary bladder cancer	0.000282	0.00053	CcSEcCtD
Rasagiline—Vomiting—Gemcitabine—urinary bladder cancer	0.000282	0.00053	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	0.000282	0.000812	CbGpPWpGaD
Rasagiline—Mental disorder—Methotrexate—urinary bladder cancer	0.00028	0.000526	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	0.00028	0.000806	CbGpPWpGaD
Rasagiline—Rash—Gemcitabine—urinary bladder cancer	0.00028	0.000525	CcSEcCtD
Rasagiline—Dermatitis—Gemcitabine—urinary bladder cancer	0.00028	0.000525	CcSEcCtD
Rasagiline—Eye disorder—Epirubicin—urinary bladder cancer	0.000279	0.000525	CcSEcCtD
Rasagiline—Hypersensitivity—Etoposide—urinary bladder cancer	0.000279	0.000524	CcSEcCtD
Rasagiline—Malnutrition—Methotrexate—urinary bladder cancer	0.000278	0.000522	CcSEcCtD
Rasagiline—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000278	0.000522	CcSEcCtD
Rasagiline—Headache—Gemcitabine—urinary bladder cancer	0.000278	0.000522	CcSEcCtD
Rasagiline—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000277	0.000521	CcSEcCtD
Rasagiline—Vomiting—Fluorouracil—urinary bladder cancer	0.000277	0.000521	CcSEcCtD
Rasagiline—Rhinitis—Doxorubicin—urinary bladder cancer	0.000277	0.000521	CcSEcCtD
Rasagiline—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000277	0.000519	CcSEcCtD
Rasagiline—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000275	0.000517	CcSEcCtD
Rasagiline—Rash—Fluorouracil—urinary bladder cancer	0.000275	0.000517	CcSEcCtD
Rasagiline—Dermatitis—Fluorouracil—urinary bladder cancer	0.000275	0.000516	CcSEcCtD
Rasagiline—BCL2—Immune System—RBX1—urinary bladder cancer	0.000274	0.000788	CbGpPWpGaD
Rasagiline—Headache—Fluorouracil—urinary bladder cancer	0.000273	0.000513	CcSEcCtD
Rasagiline—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000273	0.000513	CcSEcCtD
Rasagiline—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000272	0.000512	CcSEcCtD
Rasagiline—Dysgeusia—Methotrexate—urinary bladder cancer	0.000272	0.000511	CcSEcCtD
Rasagiline—Asthenia—Etoposide—urinary bladder cancer	0.000272	0.000511	CcSEcCtD
Rasagiline—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000272	0.00051	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000272	0.000783	CbGpPWpGaD
Rasagiline—Angiopathy—Epirubicin—urinary bladder cancer	0.000271	0.000509	CcSEcCtD
Rasagiline—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000271	0.000509	CcSEcCtD
Rasagiline—Immune system disorder—Epirubicin—urinary bladder cancer	0.00027	0.000507	CcSEcCtD
Rasagiline—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000269	0.000506	CcSEcCtD
Rasagiline—Back pain—Methotrexate—urinary bladder cancer	0.000269	0.000505	CcSEcCtD
Rasagiline—Chills—Epirubicin—urinary bladder cancer	0.000268	0.000504	CcSEcCtD
Rasagiline—Pruritus—Etoposide—urinary bladder cancer	0.000268	0.000503	CcSEcCtD
Rasagiline—Alopecia—Epirubicin—urinary bladder cancer	0.000264	0.000496	CcSEcCtD
Rasagiline—Nausea—Gemcitabine—urinary bladder cancer	0.000264	0.000495	CcSEcCtD
Rasagiline—Vomiting—Cisplatin—urinary bladder cancer	0.000263	0.000494	CcSEcCtD
Rasagiline—Mental disorder—Epirubicin—urinary bladder cancer	0.000262	0.000492	CcSEcCtD
Rasagiline—Rash—Cisplatin—urinary bladder cancer	0.000261	0.00049	CcSEcCtD
Rasagiline—Dermatitis—Cisplatin—urinary bladder cancer	0.000261	0.000489	CcSEcCtD
Rasagiline—Malnutrition—Epirubicin—urinary bladder cancer	0.00026	0.000489	CcSEcCtD
Rasagiline—Diarrhoea—Etoposide—urinary bladder cancer	0.000259	0.000487	CcSEcCtD
Rasagiline—Nausea—Fluorouracil—urinary bladder cancer	0.000259	0.000487	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000259	0.000745	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000259	0.000745	CbGpPWpGaD
Rasagiline—Eye disorder—Doxorubicin—urinary bladder cancer	0.000259	0.000485	CcSEcCtD
Rasagiline—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000258	0.000485	CcSEcCtD
Rasagiline—Anaemia—Methotrexate—urinary bladder cancer	0.000257	0.000483	CcSEcCtD
Rasagiline—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000257	0.000482	CcSEcCtD
Rasagiline—Flatulence—Epirubicin—urinary bladder cancer	0.000256	0.000482	CcSEcCtD
Rasagiline—Dysgeusia—Epirubicin—urinary bladder cancer	0.000255	0.000479	CcSEcCtD
Rasagiline—Back pain—Epirubicin—urinary bladder cancer	0.000252	0.000473	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000251	0.000724	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000251	0.000724	CbGpPWpGaD
Rasagiline—Angiopathy—Doxorubicin—urinary bladder cancer	0.000251	0.000471	CcSEcCtD
Rasagiline—Malaise—Methotrexate—urinary bladder cancer	0.000251	0.000471	CcSEcCtD
Rasagiline—Dizziness—Etoposide—urinary bladder cancer	0.000251	0.000471	CcSEcCtD
Rasagiline—Muscle spasms—Epirubicin—urinary bladder cancer	0.00025	0.00047	CcSEcCtD
Rasagiline—Immune system disorder—Doxorubicin—urinary bladder cancer	0.00025	0.000469	CcSEcCtD
Rasagiline—Vertigo—Methotrexate—urinary bladder cancer	0.00025	0.000469	CcSEcCtD
Rasagiline—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000249	0.000468	CcSEcCtD
Rasagiline—Leukopenia—Methotrexate—urinary bladder cancer	0.000249	0.000467	CcSEcCtD
Rasagiline—BCL2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	0.000249	0.000716	CbGpPWpGaD
Rasagiline—Chills—Doxorubicin—urinary bladder cancer	0.000248	0.000466	CcSEcCtD
Rasagiline—MAOB—Metabolism—RRM2—urinary bladder cancer	0.000248	0.000714	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—FGFR3—urinary bladder cancer	0.000248	0.000713	CbGpPWpGaD
Rasagiline—Nausea—Cisplatin—urinary bladder cancer	0.000246	0.000461	CcSEcCtD
Rasagiline—Alopecia—Doxorubicin—urinary bladder cancer	0.000244	0.000459	CcSEcCtD
Rasagiline—Cough—Methotrexate—urinary bladder cancer	0.000243	0.000456	CcSEcCtD
Rasagiline—Mental disorder—Doxorubicin—urinary bladder cancer	0.000242	0.000455	CcSEcCtD
Rasagiline—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000241	0.000453	CcSEcCtD
Rasagiline—Convulsion—Methotrexate—urinary bladder cancer	0.000241	0.000452	CcSEcCtD
Rasagiline—Vomiting—Etoposide—urinary bladder cancer	0.000241	0.000452	CcSEcCtD
Rasagiline—Malnutrition—Doxorubicin—urinary bladder cancer	0.000241	0.000452	CcSEcCtD
Rasagiline—Anaemia—Epirubicin—urinary bladder cancer	0.000241	0.000452	CcSEcCtD
Rasagiline—Agitation—Epirubicin—urinary bladder cancer	0.000239	0.000449	CcSEcCtD
Rasagiline—Rash—Etoposide—urinary bladder cancer	0.000239	0.000449	CcSEcCtD
Rasagiline—BCL2—Focal Adhesion—HRAS—urinary bladder cancer	0.000239	0.000688	CbGpPWpGaD
Rasagiline—Dermatitis—Etoposide—urinary bladder cancer	0.000239	0.000448	CcSEcCtD
Rasagiline—Headache—Etoposide—urinary bladder cancer	0.000237	0.000446	CcSEcCtD
Rasagiline—Flatulence—Doxorubicin—urinary bladder cancer	0.000237	0.000446	CcSEcCtD
Rasagiline—Chest pain—Methotrexate—urinary bladder cancer	0.000237	0.000445	CcSEcCtD
Rasagiline—Arthralgia—Methotrexate—urinary bladder cancer	0.000237	0.000445	CcSEcCtD
Rasagiline—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000236	0.000443	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000235	0.000442	CcSEcCtD
Rasagiline—Malaise—Epirubicin—urinary bladder cancer	0.000235	0.000441	CcSEcCtD
Rasagiline—Discomfort—Methotrexate—urinary bladder cancer	0.000234	0.000439	CcSEcCtD
Rasagiline—Vertigo—Epirubicin—urinary bladder cancer	0.000234	0.000439	CcSEcCtD
Rasagiline—Syncope—Epirubicin—urinary bladder cancer	0.000233	0.000438	CcSEcCtD
Rasagiline—Leukopenia—Epirubicin—urinary bladder cancer	0.000233	0.000437	CcSEcCtD
Rasagiline—Back pain—Doxorubicin—urinary bladder cancer	0.000233	0.000437	CcSEcCtD
Rasagiline—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000232	0.000435	CcSEcCtD
Rasagiline—MAOB—Metabolism—HPGDS—urinary bladder cancer	0.00023	0.000661	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—ENO2—urinary bladder cancer	0.00023	0.000661	CbGpPWpGaD
Rasagiline—Confusional state—Methotrexate—urinary bladder cancer	0.000229	0.00043	CcSEcCtD
Rasagiline—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000229	0.00043	CcSEcCtD
Rasagiline—Cough—Epirubicin—urinary bladder cancer	0.000227	0.000426	CcSEcCtD
Rasagiline—Convulsion—Epirubicin—urinary bladder cancer	0.000225	0.000423	CcSEcCtD
Rasagiline—Infection—Methotrexate—urinary bladder cancer	0.000225	0.000423	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000225	0.000649	CbGpPWpGaD
Rasagiline—Nausea—Etoposide—urinary bladder cancer	0.000225	0.000423	CcSEcCtD
Rasagiline—Hypertension—Epirubicin—urinary bladder cancer	0.000225	0.000422	CcSEcCtD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000224	0.000646	CbGpPWpGaD
Rasagiline—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000223	0.00042	CcSEcCtD
Rasagiline—MAOB—Metabolism—GSTT1—urinary bladder cancer	0.000223	0.000641	CbGpPWpGaD
Rasagiline—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000223	0.000418	CcSEcCtD
Rasagiline—Anaemia—Doxorubicin—urinary bladder cancer	0.000223	0.000418	CcSEcCtD
Rasagiline—Chest pain—Epirubicin—urinary bladder cancer	0.000222	0.000416	CcSEcCtD
Rasagiline—Arthralgia—Epirubicin—urinary bladder cancer	0.000222	0.000416	CcSEcCtD
Rasagiline—Agitation—Doxorubicin—urinary bladder cancer	0.000221	0.000416	CcSEcCtD
Rasagiline—Anxiety—Epirubicin—urinary bladder cancer	0.000221	0.000415	CcSEcCtD
Rasagiline—Skin disorder—Methotrexate—urinary bladder cancer	0.00022	0.000414	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.00022	0.000635	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.00022	0.000635	CbGpPWpGaD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.00022	0.000413	CcSEcCtD
Rasagiline—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000219	0.000412	CcSEcCtD
Rasagiline—Discomfort—Epirubicin—urinary bladder cancer	0.000219	0.000411	CcSEcCtD
Rasagiline—Malaise—Doxorubicin—urinary bladder cancer	0.000217	0.000408	CcSEcCtD
Rasagiline—Dry mouth—Epirubicin—urinary bladder cancer	0.000217	0.000407	CcSEcCtD
Rasagiline—Vertigo—Doxorubicin—urinary bladder cancer	0.000216	0.000406	CcSEcCtD
Rasagiline—Anorexia—Methotrexate—urinary bladder cancer	0.000216	0.000406	CcSEcCtD
Rasagiline—Syncope—Doxorubicin—urinary bladder cancer	0.000216	0.000406	CcSEcCtD
Rasagiline—Leukopenia—Doxorubicin—urinary bladder cancer	0.000216	0.000405	CcSEcCtD
Rasagiline—Confusional state—Epirubicin—urinary bladder cancer	0.000214	0.000402	CcSEcCtD
Rasagiline—Hypotension—Methotrexate—urinary bladder cancer	0.000212	0.000398	CcSEcCtD
Rasagiline—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000212	0.000397	CcSEcCtD
Rasagiline—Infection—Epirubicin—urinary bladder cancer	0.000211	0.000396	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CREBBP—urinary bladder cancer	0.000211	0.000607	CbGpPWpGaD
Rasagiline—Cough—Doxorubicin—urinary bladder cancer	0.00021	0.000395	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.00021	0.000604	CbGpPWpGaD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.00021	0.000604	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IFNA2—urinary bladder cancer	0.00021	0.000604	CbGpPWpGaD
Rasagiline—Shock—Epirubicin—urinary bladder cancer	0.000209	0.000392	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000209	0.000602	CbGpPWpGaD
Rasagiline—Convulsion—Doxorubicin—urinary bladder cancer	0.000209	0.000392	CcSEcCtD
Rasagiline—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000208	0.000391	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000208	0.0006	CbGpPWpGaD
Rasagiline—Hypertension—Doxorubicin—urinary bladder cancer	0.000208	0.00039	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000207	0.000388	CcSEcCtD
Rasagiline—Skin disorder—Epirubicin—urinary bladder cancer	0.000206	0.000387	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000206	0.000593	CbGpPWpGaD
Rasagiline—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000205	0.000386	CcSEcCtD
Rasagiline—Insomnia—Methotrexate—urinary bladder cancer	0.000205	0.000385	CcSEcCtD
Rasagiline—Chest pain—Doxorubicin—urinary bladder cancer	0.000205	0.000385	CcSEcCtD
Rasagiline—Arthralgia—Doxorubicin—urinary bladder cancer	0.000205	0.000385	CcSEcCtD
Rasagiline—Anxiety—Doxorubicin—urinary bladder cancer	0.000204	0.000384	CcSEcCtD
Rasagiline—Paraesthesia—Methotrexate—urinary bladder cancer	0.000204	0.000383	CcSEcCtD
Rasagiline—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000204	0.000382	CcSEcCtD
Rasagiline—Discomfort—Doxorubicin—urinary bladder cancer	0.000203	0.00038	CcSEcCtD
Rasagiline—Anorexia—Epirubicin—urinary bladder cancer	0.000202	0.00038	CcSEcCtD
Rasagiline—Dyspnoea—Methotrexate—urinary bladder cancer	0.000202	0.00038	CcSEcCtD
Rasagiline—Somnolence—Methotrexate—urinary bladder cancer	0.000202	0.000379	CcSEcCtD
Rasagiline—Dry mouth—Doxorubicin—urinary bladder cancer	0.0002	0.000377	CcSEcCtD
Rasagiline—Dyspepsia—Methotrexate—urinary bladder cancer	0.0002	0.000375	CcSEcCtD
Rasagiline—Hypotension—Epirubicin—urinary bladder cancer	0.000198	0.000373	CcSEcCtD
Rasagiline—BCL2—Immune System—S100B—urinary bladder cancer	0.000198	0.000571	CbGpPWpGaD
Rasagiline—Confusional state—Doxorubicin—urinary bladder cancer	0.000198	0.000372	CcSEcCtD
Rasagiline—Decreased appetite—Methotrexate—urinary bladder cancer	0.000197	0.00037	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000196	0.000368	CcSEcCtD
Rasagiline—Infection—Doxorubicin—urinary bladder cancer	0.000195	0.000367	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000194	0.000363	CcSEcCtD
Rasagiline—Shock—Doxorubicin—urinary bladder cancer	0.000193	0.000363	CcSEcCtD
Rasagiline—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000193	0.000362	CcSEcCtD
Rasagiline—Insomnia—Epirubicin—urinary bladder cancer	0.000192	0.000361	CcSEcCtD
Rasagiline—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	0.000192	0.000553	CbGpPWpGaD
Rasagiline—Skin disorder—Doxorubicin—urinary bladder cancer	0.000191	0.000358	CcSEcCtD
Rasagiline—Paraesthesia—Epirubicin—urinary bladder cancer	0.000191	0.000358	CcSEcCtD
Rasagiline—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.00019	0.000357	CcSEcCtD
Rasagiline—Dyspnoea—Epirubicin—urinary bladder cancer	0.000189	0.000356	CcSEcCtD
Rasagiline—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000189	0.000545	CbGpPWpGaD
Rasagiline—Somnolence—Epirubicin—urinary bladder cancer	0.000189	0.000355	CcSEcCtD
Rasagiline—Anorexia—Doxorubicin—urinary bladder cancer	0.000187	0.000352	CcSEcCtD
Rasagiline—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000187	0.000351	CcSEcCtD
Rasagiline—Dyspepsia—Epirubicin—urinary bladder cancer	0.000187	0.000351	CcSEcCtD
Rasagiline—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000186	0.000349	CcSEcCtD
Rasagiline—MAOB—Metabolism—NQO1—urinary bladder cancer	0.000185	0.000533	CbGpPWpGaD
Rasagiline—Decreased appetite—Epirubicin—urinary bladder cancer	0.000185	0.000347	CcSEcCtD
Rasagiline—Hypotension—Doxorubicin—urinary bladder cancer	0.000184	0.000345	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000183	0.000344	CcSEcCtD
Rasagiline—Constipation—Epirubicin—urinary bladder cancer	0.000182	0.000341	CcSEcCtD
Rasagiline—Urticaria—Methotrexate—urinary bladder cancer	0.00018	0.000339	CcSEcCtD
Rasagiline—Body temperature increased—Methotrexate—urinary bladder cancer	0.000179	0.000337	CcSEcCtD
Rasagiline—Abdominal pain—Methotrexate—urinary bladder cancer	0.000179	0.000337	CcSEcCtD
Rasagiline—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000179	0.000336	CcSEcCtD
Rasagiline—Insomnia—Doxorubicin—urinary bladder cancer	0.000178	0.000334	CcSEcCtD
Rasagiline—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000177	0.00051	CbGpPWpGaD
Rasagiline—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000176	0.000331	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—ERBB2—urinary bladder cancer	0.000176	0.000508	CbGpPWpGaD
Rasagiline—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000175	0.000329	CcSEcCtD
Rasagiline—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000175	0.000329	CcSEcCtD
Rasagiline—Somnolence—Doxorubicin—urinary bladder cancer	0.000175	0.000328	CcSEcCtD
Rasagiline—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000174	0.000326	CcSEcCtD
Rasagiline—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000173	0.000325	CcSEcCtD
Rasagiline—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000171	0.000321	CcSEcCtD
Rasagiline—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00017	0.000319	CcSEcCtD
Rasagiline—Urticaria—Epirubicin—urinary bladder cancer	0.000169	0.000317	CcSEcCtD
Rasagiline—Constipation—Doxorubicin—urinary bladder cancer	0.000168	0.000316	CcSEcCtD
Rasagiline—Abdominal pain—Epirubicin—urinary bladder cancer	0.000168	0.000315	CcSEcCtD
Rasagiline—Body temperature increased—Epirubicin—urinary bladder cancer	0.000168	0.000315	CcSEcCtD
Rasagiline—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000167	0.000314	CcSEcCtD
Rasagiline—Asthenia—Methotrexate—urinary bladder cancer	0.000163	0.000306	CcSEcCtD
Rasagiline—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000162	0.000304	CcSEcCtD
Rasagiline—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000161	0.000302	CcSEcCtD
Rasagiline—Pruritus—Methotrexate—urinary bladder cancer	0.000161	0.000302	CcSEcCtD
Rasagiline—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000156	0.000294	CcSEcCtD
Rasagiline—Urticaria—Doxorubicin—urinary bladder cancer	0.000156	0.000293	CcSEcCtD
Rasagiline—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000155	0.000292	CcSEcCtD
Rasagiline—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000155	0.000292	CcSEcCtD
Rasagiline—Diarrhoea—Methotrexate—urinary bladder cancer	0.000155	0.000292	CcSEcCtD
Rasagiline—MAOB—Metabolism—GSTP1—urinary bladder cancer	0.000154	0.000445	CbGpPWpGaD
Rasagiline—Asthenia—Epirubicin—urinary bladder cancer	0.000152	0.000286	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—CDKN1A—urinary bladder cancer	0.000151	0.000434	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—PTEN—urinary bladder cancer	0.00015	0.000433	CbGpPWpGaD
Rasagiline—Pruritus—Epirubicin—urinary bladder cancer	0.00015	0.000282	CcSEcCtD
Rasagiline—Dizziness—Methotrexate—urinary bladder cancer	0.00015	0.000282	CcSEcCtD
Rasagiline—Diarrhoea—Epirubicin—urinary bladder cancer	0.000145	0.000273	CcSEcCtD
Rasagiline—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000145	0.000272	CcSEcCtD
Rasagiline—Vomiting—Methotrexate—urinary bladder cancer	0.000144	0.000271	CcSEcCtD
Rasagiline—BCL2—Immune System—FGFR3—urinary bladder cancer	0.000144	0.000415	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—TYMS—urinary bladder cancer	0.000144	0.000413	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EP300—urinary bladder cancer	0.000143	0.000413	CbGpPWpGaD
Rasagiline—Rash—Methotrexate—urinary bladder cancer	0.000143	0.000269	CcSEcCtD
Rasagiline—Dermatitis—Methotrexate—urinary bladder cancer	0.000143	0.000268	CcSEcCtD
Rasagiline—Headache—Methotrexate—urinary bladder cancer	0.000142	0.000267	CcSEcCtD
Rasagiline—MAOB—Metabolism—GSTM1—urinary bladder cancer	0.000142	0.000409	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—NCOR1—urinary bladder cancer	0.000142	0.000409	CbGpPWpGaD
Rasagiline—Asthenia—Doxorubicin—urinary bladder cancer	0.000141	0.000265	CcSEcCtD
Rasagiline—Dizziness—Epirubicin—urinary bladder cancer	0.00014	0.000264	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—SRC—urinary bladder cancer	0.00014	0.000402	CbGpPWpGaD
Rasagiline—Pruritus—Doxorubicin—urinary bladder cancer	0.000139	0.000261	CcSEcCtD
Rasagiline—MAOB—Metabolism—GPX1—urinary bladder cancer	0.000136	0.000391	CbGpPWpGaD
Rasagiline—Vomiting—Epirubicin—urinary bladder cancer	0.000135	0.000254	CcSEcCtD
Rasagiline—Nausea—Methotrexate—urinary bladder cancer	0.000135	0.000253	CcSEcCtD
Rasagiline—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000134	0.000253	CcSEcCtD
Rasagiline—Rash—Epirubicin—urinary bladder cancer	0.000134	0.000251	CcSEcCtD
Rasagiline—Dermatitis—Epirubicin—urinary bladder cancer	0.000134	0.000251	CcSEcCtD
Rasagiline—MAOB—Metabolism—ERCC2—urinary bladder cancer	0.000133	0.000384	CbGpPWpGaD
Rasagiline—Headache—Epirubicin—urinary bladder cancer	0.000133	0.00025	CcSEcCtD
Rasagiline—Dizziness—Doxorubicin—urinary bladder cancer	0.00013	0.000244	CcSEcCtD
Rasagiline—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	0.000128	0.000369	CbGpPWpGaD
Rasagiline—Nausea—Epirubicin—urinary bladder cancer	0.000126	0.000237	CcSEcCtD
Rasagiline—MAOB—Metabolism—MTHFR—urinary bladder cancer	0.000125	0.000361	CbGpPWpGaD
Rasagiline—Vomiting—Doxorubicin—urinary bladder cancer	0.000125	0.000235	CcSEcCtD
Rasagiline—Rash—Doxorubicin—urinary bladder cancer	0.000124	0.000233	CcSEcCtD
Rasagiline—Dermatitis—Doxorubicin—urinary bladder cancer	0.000124	0.000232	CcSEcCtD
Rasagiline—Headache—Doxorubicin—urinary bladder cancer	0.000123	0.000231	CcSEcCtD
Rasagiline—BCL2—Immune System—CREBBP—urinary bladder cancer	0.000123	0.000353	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—EGFR—urinary bladder cancer	0.000122	0.000352	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDH1—urinary bladder cancer	0.000122	0.000351	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	0.000121	0.000349	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NAT1—urinary bladder cancer	0.000121	0.000349	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000119	0.000344	CbGpPWpGaD
Rasagiline—Nausea—Doxorubicin—urinary bladder cancer	0.000117	0.000219	CcSEcCtD
Rasagiline—BCL2—Innate Immune System—KRAS—urinary bladder cancer	0.000116	0.000333	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	0.000111	0.00032	CbGpPWpGaD
Rasagiline—BCL2—Immune System—ERBB2—urinary bladder cancer	0.000103	0.000296	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PPARG—urinary bladder cancer	0.000102	0.000293	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	9.99e-05	0.000288	CbGpPWpGaD
Rasagiline—BCL2—Innate Immune System—HRAS—urinary bladder cancer	9.82e-05	0.000283	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—CREBBP—urinary bladder cancer	9.77e-05	0.000281	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	9.44e-05	0.000272	CbGpPWpGaD
Rasagiline—BCL2—Immune System—IL2—urinary bladder cancer	9.31e-05	0.000268	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	9.19e-05	0.000265	CbGpPWpGaD
Rasagiline—BCL2—Immune System—CDKN1A—urinary bladder cancer	8.78e-05	0.000253	CbGpPWpGaD
Rasagiline—BCL2—Immune System—PTEN—urinary bladder cancer	8.76e-05	0.000252	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EP300—urinary bladder cancer	8.36e-05	0.000241	CbGpPWpGaD
Rasagiline—BCL2—Immune System—SRC—urinary bladder cancer	8.13e-05	0.000234	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTGS2—urinary bladder cancer	8e-05	0.00023	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	7.37e-05	0.000212	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TYMP—urinary bladder cancer	7.35e-05	0.000212	CbGpPWpGaD
Rasagiline—BCL2—Immune System—EGFR—urinary bladder cancer	7.12e-05	0.000205	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	7.06e-05	0.000203	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—PTEN—urinary bladder cancer	6.98e-05	0.000201	CbGpPWpGaD
Rasagiline—BCL2—Immune System—KRAS—urinary bladder cancer	6.73e-05	0.000194	CbGpPWpGaD
Rasagiline—MAOB—Metabolism—EP300—urinary bladder cancer	6.65e-05	0.000192	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NAT2—urinary bladder cancer	6.65e-05	0.000191	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—RRM2—urinary bladder cancer	5.74e-05	0.000165	CbGpPWpGaD
Rasagiline—BCL2—Immune System—HRAS—urinary bladder cancer	5.72e-05	0.000165	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	5.31e-05	0.000153	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ENO2—urinary bladder cancer	5.31e-05	0.000153	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	5.28e-05	0.000152	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	5.15e-05	0.000148	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	5.08e-05	0.000146	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NQO1—urinary bladder cancer	4.28e-05	0.000123	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	4.16e-05	0.00012	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	3.62e-05	0.000104	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	3.57e-05	0.000103	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	3.46e-05	9.96e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—TYMS—urinary bladder cancer	3.32e-05	9.57e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	3.28e-05	9.46e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	3.28e-05	9.46e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—GPX1—urinary bladder cancer	3.14e-05	9.06e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	3.09e-05	8.89e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.9e-05	8.36e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PPARG—urinary bladder cancer	2.35e-05	6.78e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	2.26e-05	6.51e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.85e-05	5.33e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.61e-05	4.65e-05	CbGpPWpGaD
Rasagiline—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.54e-05	4.43e-05	CbGpPWpGaD
